Univar (UNVR) Expands Pharmaceutical Ingredients in EMEA
Univar Solutions Inc. UNVR announced the expansion of its Pharmaceutical Ingredients as a Dedicated Industry Vertical across Europe, the Middle East and Africa. Through the launch, the company continues to invest in its dedicated model.
The new group allows Univar to serve the pharmaceutical ingredients market worldwide with expertise in all major regions. This is supported by a global network of state-of-the-art Solutions Centers geared to meet the increasing demand of customers.
Univar now has a fully worldwide approach for the pharmaceutical ingredients market due to the combination of the new industry vertical team with the already successful organizations operating in North and Latin America.
Per management, the organizational alignment will improve efficiency and increase emphasis on the needs of customers and suppliers of pharmaceutical ingredients. It will also strengthen the company’s commitment to be a responsible provider of solutions.
Notably, Univar launched the business line with its dedicated management, resources and approach to the market to create greater value through specialization.
The company envisions that the expertise provided by a dedicated sales and technical team will strengthen its relationships with suppliers and customers. Notably, the change was made to adapt to the change in market needs and offer a greater depth of focus, eventually bringing value to its suppliers and customers.
Univar’s emphasis on Pharma provides a guarantee to suppliers and customers that it proactively handles short-term regulatory changes and the impacts of the same on its business.
The company’s shares have dipped 5.9% over a year compared with a 29% decline recorded by its industry.
In November 2019, Univar revised the adjusted EBITDA forecast for 2019, factoring in the lower-than-expected demand for chemicals and ingredients. Further, it expects adjusted EBITDA of $700-$725 million for the year compared with $725-$740 million mentioned earlier.
Moreover, the company expects adjusted EBITDA of $155-$180 million for the fourth quarter of 2019, suggesting a rise from $144 million reported in the year-ago quarter.
Univar Inc. Price and Consensus
Univar Inc. price-consensus-chart | Univar Inc. Quote
Zacks Rank & Stocks to Consider
Univar currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the basic materials space are Daqo New Energy Corp. DQ, Sandstorm Gold Ltd SAND and Commercial Metals Company CMC.
Daqo New Energy has a projected earnings growth rate of 353.7% for 2020. The company’s shares have rallied 118.5% in a year. It currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Sandstorm Gold has an estimated earnings growth rate of 66.7% for fiscal 2020. It currently flaunts a Zacks Rank #1. The company’s shares have rallied 29.1% in a year.
Commercial Metals presently has a Zacks Rank #2 (Buy) and a projected earnings growth rate of 20.2% for 2020. The company’s shares have rallied 23.6% in a year.
Free: Zacks’ Single Best Stock Set to Double
Today you are invited to download our latest Special Report that reveals 5 stocks with the most potential to gain +100% or more in 2020. From those 5, Zacks Director of Research, Sheraz Mian hand-picks one to have the most explosive upside of all.
This pioneering tech ticker had soared to all-time highs and then subsided to a price that is irresistible. Now a pending acquisition could super-charge the company’s drive past competitors in the development of true Artificial Intelligence. The earlier you get in to this stock, the greater your potential gain.
See 5 Stocks Set to Double>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Sandstorm Gold Ltd (SAND) : Free Stock Analysis Report
Commercial Metals Company (CMC) : Free Stock Analysis Report
DAQO New Energy Corp. (DQ) : Free Stock Analysis Report
Univar Inc. (UNVR) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
